Next Article in Journal
Frailty in Stroke—A Narrated Review
Previous Article in Journal
Contributions to a Discussion of Spinosaurus aegyptiacus as a Capable Swimmer and Deep-Water Predator
Previous Article in Special Issue
Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 11
Issue 9
10.3390/life11090890
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Liquid Biopsy, ctDNA Diagnosis through NGS

by
Chen Lin
1,
Xuzhu Liu
1,
Bingyi Zheng
2,3,
Rongqin Ke
1,* and
Chi-Meng Tzeng
2,3,*
1
School of Medicine, Huaqiao University, Quanzhou 362021, China
2
Translational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China
3
Xiamen Key Laboratory of Cancer Cell Theranostics and Clinical Translation, Xiamen 361102, China
*
Authors to whom correspondence should be addressed.
Life 2021, 11(9), 890; https://doi.org/10.3390/life11090890
Submission received: 16 July 2021 / Revised: 8 August 2021 / Accepted: 11 August 2021 / Published: 28 August 2021
(This article belongs to the Special Issue The Increasing Role of Next Generation Sequencing Methods in Mutation Analysis)
Browse Figure
Review Reports Versions Notes

Abstract

Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains information of genetic alterations. Compared to tissue biopsy, liquid biopsy possesses great advantages such as a less demanding procedure, minimal invasion, ease of frequent sampling, and less sampling bias. Next-generation sequencing (NGS) methods have come to a point that both the cost and performance are suitable for clinical diagnosis. Thus, profiling ctDNA by NGS technologies is becoming more and more popular since it can be applied in the whole process of cancer diagnosis and management. Further developments of liquid biopsy ctDNA testing will be beneficial for cancer patients, paving the way for precision medicine. In conclusion, profiling ctDNA with NGS for cancer diagnosis is both biologically sound and technically convenient.
Keywords: liquid biopsy; ctDNA; next-generation sequencing; mutation; biomarkers liquid biopsy; ctDNA; next-generation sequencing; mutation; biomarkers

Share and Cite

MDPI and ACS Style

Lin, C.; Liu, X.; Zheng, B.; Ke, R.; Tzeng, C.-M. Liquid Biopsy, ctDNA Diagnosis through NGS. Life 2021, 11, 890. https://doi.org/10.3390/life11090890

AMA Style

Lin C, Liu X, Zheng B, Ke R, Tzeng C-M. Liquid Biopsy, ctDNA Diagnosis through NGS. Life. 2021; 11(9):890. https://doi.org/10.3390/life11090890

Chicago/Turabian Style

Lin, Chen, Xuzhu Liu, Bingyi Zheng, Rongqin Ke, and Chi-Meng Tzeng. 2021. "Liquid Biopsy, ctDNA Diagnosis through NGS" Life 11, no. 9: 890. https://doi.org/10.3390/life11090890

APA Style

Lin, C., Liu, X., Zheng, B., Ke, R., & Tzeng, C.-M. (2021). Liquid Biopsy, ctDNA Diagnosis through NGS. Life, 11(9), 890. https://doi.org/10.3390/life11090890

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop